bullish reduc price
top line varian gener revenu million versu estim
million consensu estim million oncolog system
revenu million versu estim million proton
solut segment deliv million revenu versu estim
million revenu million versu estim
million gross oncolog system order quarter increas report
constant currenc materi slowdown due impact covid-
bottom line varian report non-gaap ep figur quarter
versu expect consensu estim heavier-than-
anticip oper expens primari reason slight profit
miss rel model
balanc sheet cash flow varian end quarter cash
equival approxim million around million debt
flow oper quarter million capit expenditur
million
outlook varian withdrew previous provid financi guidanc
remind compani recent guidanc includ assumpt
revenu growth march confer call manag withdrew
previou profit guidanc rang non-gaap
ep vs current model non-gaap ep
billion revenu assum revenu growth
non-gaap ep
recommend maintain outperform invest rate
share reduc price target given reduc
expect near-term profit due fallout arriv
price target attach multipl adjust ebitda estim
assum approxim million net cash month
revenu mil estimate bold
ep estimate bold
upsid price
return equiti ltm
note pleas refer page end
report import disclosur
overal varian result slightli model given backdrop
crisi would consid number larg line order momentum
oncolog slow materi remain slightli posit final varian manag
withdrew previous provid financi guidanc action par
cours compani current therefor surpris
revenu look revenu oper segment oncolog system revenu came
million estim million revenu segment increas
versu compar period last year product revenu oncolog system
declin quarter report servic increas report
posit impact grow instal base long-term contract cite driver
strong servic perform
varian proton solut segment deliv million revenu declin around
versu compar quarter last year estim difficult-to-model
busi million
varian revenu segment deliv million revenu versu estim
gross margin oper expens total consolid gross margin came
versu estim non-gaap gross margin
increas bp versu last year compar quarter quarter result
benefit product mix tariff exclus partial off-set factori
cost oncolog system gener gross margin flat result versu
period year ago proton busi slightli neg gross margin final
small revenu segment gener gross margin quarter
sg expens came revenu expect non-
sg expens compani recent begun take step
reduc sg expens given backdrop expens
revenu versu model despit uncertainti
current anticip materi reduct varian invest
profit non-gaap ep came versu estim
consensu expect also
balanc sheet cash flow varian end quarter cash equival
approxim million million debt flow oper
million quarter result repres million increas versu
period last year said favor time cite improv yoy
varian report slightli disappoint quarter rel model given
massiv uncertainti relat pandem seem inappropri
especi march quarter dwell much rel small shortfal
revenu profit compani order momentum oncolog servic slow
meaning way still slightli posit final manag withdrew
previous provid financi guidanc line decis made
compani given on-going issu
remind varian origin financi guidanc includ expect
overal revenu growth reduc growth march
non-gaap ep withdrawn varian march updat
confer call oper cash flow million also withdrawn
march
constant currenc evid
current model non-gaap ep billion
revenu anticip slightli neg revenu comparison full-year
rel complet conced convict level abl
dial precis impact quit low varian may well deliv
consider better top-lin result model suggest
oncolog system revenu million grew approxim dollar
constant currenc quarter america region deliv revenu
growth despit difficult march revenu emea region declin
report flat constant currenc region also face materi top-lin
headwind march final asia-pacif region revenu increas
report show growth
region
demonstr level recoveri late quarter impact
began reced bit
oncolog system order grew report constant currenc
result repres materi slowdown rel recent perform
gener track upper-single-digit growth rang averag past year
long-term prospect segment remain quit bullish littl doubt
impact continu overhang busi near term
america gross oncolog order million declin
europ middl east india africa region gross oncolog order increas
dollar million constant currenc final gross oncolog
order asia-pacif region million declin
compani believ approxim million revenu america
emea region neg impact relat delay quarter
gross order believ declin million america region
due impact late quarter
compani net instal base radiat therapi stand unit
result repres growth versu period last year slight sequenti
growth well
win quarter includ sever sizabl truebeam system order
america region larg order russia includ truebeam halcyon
system one vitalbeam truebeam five halcyon order
sever meaning order throughout apac region includ china thailand
singapor japan
compani receiv order etho unit quarter etho
commerci avail short time month place total unit
order close compani believ earli feedback
early-adopt etho custom strong workflow superior
repeatedli cite one product key differenti
varian continu see strong demand high margin softwar solut
softwar revenu increas quarter uniqu softwar custom also grew
approxim quarter servic revenu aid materi
recent activ organ servic revenu growth approxim
final hardwar revenu consider impact declin
varian proton solut busi gener million revenu
quarter book two new order apac region
compani unfortun forc take impair charg
relat proton solut busi time impair associ
varian loan receiv california proton therapi center due cptc
oper market challeng impair amount million multi-
quarter downturn economi would certainli escal risk addit
compani segment gener million quarter includ
var intervent oncolog busi remind busi includ asset
cryoablat embol microspher microwav ablat cardiac
radioabl current attract gross margin profil lose money
oper line scale busi also gener solid oper margin
manag disclos varian complet sever previous delay
product instal china month april certainli encourag
term specif market sure mean much
countri still materi impact signific number new case
varian look reduc sg expens footprint next sever month
cite travel new hire two area compani could quickli captur
appear varian chang much term invest
time compani believ mani project creat signific long-term
valu varian remain hope crisi begin materi
reced potenti cut budget would need serious consid
compani continu activ share repurchas activ
repurchas share approxim million quarter
said compani state halt share repurchas activ time given
uncertainti relat pandem
radiat therapi certainli view elect hospit decision-
maker region still ravag may view time new
invest high end cancer equip someth push
quarter longer believ delay larger capit equip purchas like
path mani hospit face near-term financi challeng result
headwind therefor think varian hardwar busi like face
materi headwind america region even emea region extent
next two four quarter attempt captur headwind within
model
varian immun market challeng particularli
pressur persist beyond next quarter two think compani well
posit weather storm despit histor pandem econom downturn
varian signific balanc sheet strength long-standing commit innov
among key factor provid us signific long-term confid
maintain outperform invest rate share cut
price target given reduc profit expect
challeng associ backdrop arriv price target
attach multipl adjust ebitda estim assum around
million net cash month
revenu
interest incom net
 revenu
sg revenu
million except per share data
 xpec ted per rket ver ne xt th
oun im ovi ng mp ny fun da ntal
 xpec ted pe rfo rm ro ug ly ket ver th ne nth
lon -te po te nti xi ts bu nea -te rm ca ta ly ap
 xpec ted un de er fo rm th rk et ov er xt th
fu valu ov r- va lu ed cu le vel
de velo pri ce ta get fo thi com pa ny use /e da th ere
ri ks th ur ta rg ri ce wi chiev clud ut ot im ite fai lure
com ny ur ven ear stim te
th fo wi ng li ra tin fo com pa nie cover rr ton ea ch socia te
inc ch com es ra te ut pe rfo rm wa nd
rep se te al co pa ni es ov ra ist um com pa nie ate
 et rf rm es nted al com ni es th co ver ag ist
th um er co ani ra te un erp fo wa se nted al
comp nie
sso ciat inc provid ed inv tm ank ing se vice withi mo nth
th co pa ni es th ad tp fo rm tin gs th
comp nie th et fo rm ratin gs th om ani th ha
na ly er tific ion sea rc na yst sp ns ib le fo th prep aratio th es ea ch po ich ae pe tu sk fa er eb ce rti fi es
th vi ws th om pa nd th ei secu iti xpress rep rt accur atel efl ct hi per na op ni on lyst also
certi fi es tha art hi com pe nsati di ctl dir ctli el te th peci fic co mm en ati vie co ntain th ort
 es ear ch na lyst cl udi th os vo lv ed th pr ep ati thi rep rt ce ive ct om nsatio co ne cti wi th th firm
stm nt ank ing ctivi tie ali st co pe ns ati wh ich de sa la nd nu ba se po ume us facto rs inclu din
sto ck pr ice pe rfor man ce qu al iti al ysi nv sto cl ie nt feed ack al profita il iti th fi rm wh ch mpa cte
firm us ess cti viti nd incl ude ng oth th gs tituti nal qu iti tr ad nv es tme ba nk servi ce
vestm ent ba king ser vic es de fi ne de le cl ud es oth thi ng ac tin un de wri ter er
 elli gr ou secu ri tie de rw riti al yst esp si ble th rep ort hael etusk fa em er alyst
 ou eh old es sh th co sto ck th co pa sd gu la tion op te le tha proh ib se rc al yst
tra ing se cu ri tie co vere com ani es dur sp ec ifi tim per iod nd fter th pu li catio es rch epo rt
 arr ton sea rch socia te fu -ser vic fi na nci al se vic es firm th ffer wid var ie ty ser vic es pr odu ts lie ts
vesto rs sho ld ass ume tha arr gton ea ch ee ing ill see stm en ba king oth us ess la ti onsh ith th
com es nd ts rese arc co er ge ar rin rese arc ceiv ed nve tmen ki ng- rel ate co pensa tio thi
com ith th past nth oe exp ct wi th th ne xt th mo nth
barrington research associ inc finra-regist broker/deal clear wedbush secur fulli
disclos basi conveni client offer sever way client facilit payment
trade barrington research order may place trade desk
trader michael hutchison head trader christoph pari email address
instant messeng address brrrmh
trade broker trade may also stepped-in barrington research trade execut broker
commiss share arrang barrington commiss share agreement numer broker wall
street complet list commiss share program barrington research particip pleas contact
salesperson trade desk
follow list provid barrington research trade alloc settlement id wedbush dtc code
question trade set account relat inform pleas call trade depart
inform contain herein obtain sourc believ reliabl guarante accuraci complet
opinion estim reflect best judgment report date subject chang without notic report intend inform
purpos constitut offer solicit buy sell secur barrington research associ inc affili offic
analyst employe may time time posit secur refer herein barrington research associ inc may act
princip agent buyer seller purchas sale secur mention report barrington research associ
inc may provid may seek provid invest bank servic compani mention report report may
reproduc form without prior written consent barrington research associ inc right reserv member finra/sipc
